Document is current
Any future updates will be listed below
-
Authors
Riek, Myriam
Scherer, Almut
Möller, Burkhard
Ciurea, Adrian
von Mühlenen, Ines
Gabay, Cem
Kyburz, Diego
Brulhart, Laure
von Kempis, Johannes
Mueller, Ruediger B.
Hasler, Paul
Strahm, Tanja
von Känel, Sabine
Zufferey, Pascal
Dudler, Jean
Finckh, Axel
-
Funding
Funding for this research was provided by:
Pfizer Switzerland, Switzerland (53232357)
- License Information
-
More Information
Article History
Received: 14 December 2022
Accepted: 12 October 2023
First Online: 18 October 2023
Competing interests
: MR: none apart from being partly paid by this study’s grant; AS: none apart from being partly paid by this study’s grant; BM: received speaker fees from BMS, Eli Lilly, Janssen-Cilag, MSD, Novartis, and Synergy, conference expenditures from AbbVie and Pfizer, research grants from Celgene / Amgen to the exclusive benefit of SCQM; AC: received speaker or consulting fees from AbbVie, MSD, and Novartis; IvM: none; CG: received grant support from AB2 Bio LTD; DK: received speaker or consulting fees from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, and Pfizer; LB: none; JvK: received speaker or consulting fees from AbbVie, BMS, Boehringer-Ingelheim, GSK, Menarini, Novartis, Pfizer, and Sandoz; RBM: none; PH: none; TS: none apart from being partly paid by this study’s grant; SvK: none apart from being partly paid by this study’s grant; PZ: none apart from being partly paid by this study’s grant; JD: none; AF: received speaker or consulting fees from AbbVie, Eli Lilly, Pfizer, and Viatris and grant support from AbbVie, Eli Lilly, Galapagos, and Pfizer.
